La Jolla Pharmaceutical Company Announces Initiation of Multicenter, Randomized, Phase 2 Clinical Study of LJPC‑401 in Patients ...
SAN DIEGO, Dec. 18, 2017 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (NASDAQ:LJPC) (the Company or La Jolla) today announced the initiation of LJ401-HH01, a Phase 2 clinical study of LJPC‑401 (synthetic human hepcidin) in patients with hereditary …